Exelixis Company Leadership

EXEL Stock  USD 43.92  1.22  2.86%   
Exelixis' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Exelixis suggests that most insiders are panicking. Exelixis employs about 1.1 K people. The company is managed by 19 executives with a total tenure of roughly 75 years, averaging almost 3.0 years of service per executive, having 60.37 employees per reported executive.
Michael Morrissey  CEO
CEO and President and Director
Stelios Papadopoulos  Chairman
Chairman and Member of Audit Committee

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-11-21Patrick J HaleyDisposed 28043 @ 42.58View
2025-11-20Patrick J HaleyDisposed 34187 @ 41.88View
2025-11-12Stelios PapadopoulosDisposed 100000 @ 43.55View
2025-11-11Mary C BeckerleDisposed 24622 @ 41.93View
2025-06-03Jack L WyszomierskiDisposed 7535 @ 43.09View
2025-06-02Sue Gail EckhardtDisposed 18838 @ 42.74View
2025-05-21Tomas J HeymanDisposed 4544 @ 44.29View
2025-05-20Patrick J HaleyDisposed 34387 @ 44.06View
2025-05-16George PosteDisposed 20634 @ 45.99View
2025-05-15Stelios PapadopoulosDisposed 36508 @ 44.35View
2025-05-14Patrick J HaleyDisposed 10000 @ 42.68View
2025-05-01Dana AftabDisposed 1508 @ 39View
2025-03-03Patrick J HaleyDisposed 10000 @ 38.8View
2025-02-28Jack L WyszomierskiDisposed 8768 @ 37.8View
Monitoring Exelixis' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.

Exelixis' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Exelixis' future performance. Based on our forecasts, it is anticipated that Exelixis will maintain a workforce of about 1150 employees by March 2026.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Exelixis Management Team Effectiveness

The company has return on total asset (ROA) of 0.1926 % which means that it generated a profit of $0.1926 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3553 %, meaning that it created $0.3553 on every $100 dollars invested by stockholders. Exelixis' management efficiency ratios could be used to measure how well Exelixis manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.07. The value of Return On Capital Employed is expected to slide to 0.07. At this time, Exelixis' Other Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 2.9 B this year, although the value of Return On Tangible Assets will most likely fall to 0.07.
Net Income Applicable To Common Shares is expected to rise to about 220.1 M this year, although the value of Common Stock Shares Outstanding will most likely fall to about 188.7 M. Exelixis holds a total of 259.71 Million outstanding shares. The majority of Exelixis outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Exelixis to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Exelixis. Please pay attention to any change in the institutional holdings of Exelixis as this could imply that something significant has changed or is about to change at the company. Also note that almost five million twelve thousand three hundred seventy-eight invesors are currently shorting Exelixis expressing very little confidence in its future performance.
 
Shares in Circulation  
First Issued
1999-12-31
Previous Quarter
278.5 M
Current Value
281.9 M
Avarage Shares Outstanding
181.9 M
Quarterly Volatility
107 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Some institutional investors establish a significant position in stocks such as Exelixis in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Exelixis, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Exelixis Workforce Comparison

Exelixis is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 38,724. Exelixis holds roughly 1,147 in number of employees claiming about 2.96% of equities under Health Care industry.

Exelixis Profit Margins

The company has Profit Margin (PM) of 0.34 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.39 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.39.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.140.9604
Fairly Up
Slightly volatile

Exelixis Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exelixis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exelixis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Exelixis insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2026-03-01
1.0
4
4
 956,633 
 239,569 
2025-12-01
0.3571
5
14
 215,707 
 617,611 
2025-06-01
0.6207
18
29
 819,533 
 1,621,661 
2025-03-01
0.7838
29
37
 3,152,268 
 1,075,672 
2024-12-01
0.2308
6
26
 1,002,386 
 2,171,397 
2024-09-01
0.2857
4
14
 320,000 
 746,540 
2024-06-01
0.6957
16
23
 683,574 
 288,514 
2024-03-01
1.8889
17
9
 1,441,661 
 224,205 
2023-12-01
0.3333
3
9
 287,302 
 445,471 
2023-09-01
0.5
11
22
 1,351,531 
 1,321,108 
2023-06-01
1.6667
20
12
 1,078,215 
 145,344 
2023-03-01
0.4545
10
22
 493,354 
 775,123 
2022-12-01
0.2727
3
11
 166,010 
 278,919 
2022-09-01
0.875
7
8
 478,419 
 285,776 
2022-06-01
1.0909
12
11
 305,861 
 230,808 
2022-03-01
0.375
9
24
 914,480 
 542,071 
2021-12-01
0.3939
13
33
 619,300 
 1,025,454 
2021-09-01
0.7368
14
19
 591,917 
 743,816 
2021-06-01
0.8065
25
31
 867,881 
 1,231,747 
2021-03-01
0.7674
33
43
 1,857,031 
 1,436,618 
2020-12-01
0.3659
15
41
 2,238,245 
 1,463,501 
2020-09-01
0.6429
18
28
 782,704 
 1,148,835 
2020-06-01
0.6552
57
87
 3,454,824 
 5,218,744 
2020-03-01
0.5625
27
48
 1,016,359 
 1,489,913 
2019-12-01
0.3871
12
31
 522,117 
 710,489 
2019-09-01
0.5484
17
31
 511,967 
 863,981 
2019-06-01
1.2059
41
34
 1,207,728 
 1,006,147 
2019-03-01
0.4487
35
78
 837,010 
 1,714,946 
2018-12-01
0.175
7
40
 130,146 
 466,213 
2018-09-01
0.7083
17
24
 1,517,131 
 1,229,228 
2018-06-01
1.0
37
37
 867,758 
 1,109,774 
2018-03-01
0.5714
12
21
 136,918 
 297,947 
2017-12-01
1.2
12
10
 1,437,500 
 21,781 
2017-09-01
0.25
6
24
 293,969 
 1,425,244 
2017-06-01
1.0323
32
31
 840,541 
 1,220,297 
2017-03-01
0.4898
24
49
 682,877 
 1,539,985 
2016-12-01
0.5455
12
22
 827,332 
 1,399,058 
2016-09-01
2.6667
16
6
 1,269,263 
 455,244 
2016-06-01
21.0
21
1
 1,535,000 
 200,000 
2016-03-01
5.0
25
5
 1,575,819 
 134,215 
2015-12-01
0.8333
20
24
 457,633 
 762,362 
2015-09-01
9.0
18
2
 3,912,000 
 170,000 
2014-12-01
1.7778
16
9
 563,565 
 13,891 
2014-09-01
1.0
2
2
 20,000 
 46,800 
2014-06-01
3.0
9
3
 360,000 
 13,000 
2014-03-01
0.6364
7
11
 242,268 
 15,169 
2013-12-01
1.125
18
16
 750,129 
 24,034 
2013-09-01
1.1429
16
14
 1,575,217 
 44,003 
2013-06-01
1.3077
17
13
 315,904 
 20,522 
2013-03-01
0.5385
7
13
 14,246 
 20,474 
2012-12-01
0.75
18
24
 77,333 
 52,836 
2012-09-01
0.8125
13
16
 1,031,454 
 61,940 
2012-06-01
1.0
16
16
 162,264 
 23,760 
2012-03-01
0.5
6
12
 12,267 
 50,054 
2011-12-01
1.1667
7
6
 212,265 
 12,265 
2011-09-01
1.75
14
8
 973,177 
 15,469 
2011-06-01
2.2222
20
9
 169,217 
 18,592 
2011-03-01
1.0
9
9
 74,376 
 74,376 
2010-12-01
0.8182
9
11
 104,427 
 157,216 
2010-09-01
69.0
69
1
 482,700 
 2,000 
2010-03-01
2.0
2
1
 70,000 
 8,000 
2009-12-01
4.0
28
7
 2,367,350 
 36,529 
2009-09-01
1.5556
28
18
 764,675 
 931,000 
2009-06-01
1.2857
9
7
 101,250 
 18,806 
2008-09-01
1.0
1
1
 185,000 
 0.00 
2007-12-01
0.0455
7
154
 1,225,000 
 30,625 
2007-09-01
0.0345
2
58
 90,000 
 18,125 
2007-06-01
0.0427
10
234
 92,108 
 44,841 
2007-03-01
0.0106
2
188
 65,000 
 150,000 
2006-12-01
0.0486
9
185
 1,064,000 
 32,500 
2006-09-01
0.0048
1
209
 175,000 
 32,500 
2006-06-01
0.0727
20
275
 135,624 
 153,748 
2006-03-01
0.0199
5
251
 13,971 
 56,449 
2005-12-01
0.0354
8
226
 2,340,000 
 112,500 
2005-09-01
0.0476
1
21
 60,000 
 278,486 
2005-06-01
0.15
9
60
 90,000 
 10,000 
2005-03-01
0.0047
1
212
 25,000 
 32,500 
2004-12-01
0.0444
8
180
 920,000 
 32,500 
2004-09-01
0.0117
2
171
 32,500 
 252,500 
2004-06-01
0.1507
11
73
 175,000 
 12,500 
2004-03-01
0.0952
12
126
 260,000 
 43,116 
2003-12-01
0.0783
13
166
 1,565,000 
 1,749,708 
2003-09-01
0.0476
1
21
 25,000 
 29,753 
2003-06-01
0.7143
5
7
 25,000 
 72,000 

Exelixis Notable Stakeholders

An Exelixis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Exelixis often face trade-offs trying to please all of them. Exelixis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Exelixis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael MorrisseyCEO and President and DirectorProfile
Stelios PapadopoulosChairman and Member of Audit CommitteeProfile
Susan HubbardExecutive Vice President - Public Affairs and Investor RelationsProfile
Christopher SennerCFO, Executive Vice PresidentProfile
Peter LambChief Scientific Officer and Executive VP of Discovery ResearchProfile
Stefan KraussVP DevelopmentProfile
Laura DillardExecutive ResourcesProfile
Tony RedmondSenior ResourcesProfile
Brenda JDGeneral CounselProfile
Gregg BernierVP MarketingProfile
William MDSenior AffairsProfile
Amy MDExecutive OfficerProfile
Patrick MBAExecutive CommercialProfile
Dana AftabExecutive DevelopmentProfile
Jeffrey JDExecutive CounselProfile
Anne MDSenior SafetyProfile
Andrew PetersSenior StrategyProfile
MBA MBAEx CommercialProfile
Deborah CPASenior ControllerProfile
String symbol = request.getParameter("s");

About Exelixis Management Performance

The success or failure of an entity such as Exelixis often depends on how effective the management is. Exelixis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Exelixis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Exelixis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.28  0.07 
Return On Capital Employed 0.36  0.07 
Return On Assets 0.28  0.07 
Return On Equity 0.36  0.09 

Exelixis Workforce Analysis

Traditionally, organizations such as Exelixis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Exelixis within its industry.

Exelixis Manpower Efficiency

Return on Exelixis Manpower

Revenue Per Employee2M
Revenue Per Executive122.1M
Net Income Per Employee682.3K
Net Income Per Executive41.2M
Working Capital Per Employee904.7K
Working Capital Per Executive54.6M
When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. Projected growth potential of Exelixis fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Exelixis assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
0.842
Earnings Share
2.86
Revenue Per Share
8.543
Quarterly Revenue Growth
0.056
Return On Assets
0.1926
Investors evaluate Exelixis using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exelixis' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Exelixis' market price to deviate significantly from intrinsic value.
It's important to distinguish between Exelixis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Exelixis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Exelixis' market price signifies the transaction level at which participants voluntarily complete trades.